<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1760</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2024-20-3-117-129</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PENILE CANCER</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак полового члена</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Prognostic factors affecting survival of patients with penile cancer receiving treatment in wide clinical practice</article-title><trans-title-group xml:lang="ru"><trans-title>Прогностические факторы, влияющие на показатели выживаемости у больных раком полового члена, получавших лечение в широкой клинической практике</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4109-6451</contrib-id><name-alternatives><name xml:lang="en"><surname>Shirokorad</surname><given-names>V. I.</given-names></name><name xml:lang="ru"><surname>Широкорад</surname><given-names>В. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>27 Istra, Moscow Region 143515</italic></p></bio><bio xml:lang="ru"><p><italic>143515 Московская область, п. Истра, 27</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4494-1489</contrib-id><name-alternatives><name xml:lang="en"><surname>Kostritskiy</surname><given-names>S. V.</given-names></name><name xml:lang="ru"><surname>Кострицкий</surname><given-names>С. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold> Stanislav V. Kostritskiy</bold></p><p><italic>27 Istra, Moscow Region 143515</italic></p></bio><bio xml:lang="ru"><p><bold>Кострицкий Станислав Викторович</bold>  - врач-онколог онкоурологического отделения </p><p><italic>143515 Московская область, п. Истра, 27</italic></p></bio><email>Stas.medic@bk.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4335-8446</contrib-id><name-alternatives><name xml:lang="en"><surname>Semenov</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Семенов</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>7–9 Universitetskaya Naberezhnaya, Saint Petersburg 199034,</italic></p><p><italic>56 Prospekt Veteranov, Saint Petersburg 198255</italic></p></bio><bio xml:lang="ru"><p><italic>199034 Санкт-Петербург, Университетская наб., 7–9,</italic></p><p><italic>198255 Санкт-Петербург, пр-кт Ветеранов, 56 </italic></p></bio><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6783-9519</contrib-id><name-alternatives><name xml:lang="en"><surname>Yakubova</surname><given-names>D. D.</given-names></name><name xml:lang="ru"><surname>Якубова</surname><given-names>Д. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>27 Istra, Moscow Region 143515</italic></p></bio><bio xml:lang="ru"><p><italic>143515 Московская область, п. Истра, 27</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Moscow City Oncological Hospital No. 62, Moscow Healthcare Department</institution></aff><aff><institution xml:lang="ru">ГБУЗ г. Москвы «Московская городская онкологическая больница № 62 Департамента здравоохранения г. Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Saint Petersburg State University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Санкт-Петербургский государственный университет»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">City Clinical Oncological Dispensary</institution></aff><aff><institution xml:lang="ru">СПб ГБУЗ «Городской клинический онкологический диспансер»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-11-24" publication-format="electronic"><day>24</day><month>11</month><year>2024</year></pub-date><volume>20</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>117</fpage><lpage>129</lpage><history><date date-type="received" iso-8601-date="2023-12-25"><day>25</day><month>12</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-09-30"><day>30</day><month>09</month><year>2024</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1760">https://oncourology.abvpress.ru/oncur/article/view/1760</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold><bold> </bold>To evaluate the effect of prognostic factors on survival rates of patients with penile cancer and to identify groups of patients with favorable and unfavorable prognoses.</p><p><bold>Materials and methods. </bold>Retrospective analysis of data of 197 patients with penile cancer who were treated at the Moscow City Oncological Hospital No. 62 and Clinical Oncological Dispensary (Omsk) between 1997 and 2023 was performed.</p><p><bold>Results. </bold>Statistically significant prognostic factors affecting survival rates of patients with penile cancer according to univariate analysis (<italic>log-rank </italic>test with <italic>p </italic>&lt;0.05) and multivariate Cox regression analysis are: clinical stage (I–IV), T stage (T1–T3), resection margin (R0–R1), N grade (N0–N3), lymphovascular invasion, extranodal extension of metastasis to the inguinal lymph nodes, necrosis of the primary tumor, iliac lymph node involvement. Factors without significant effect on survival are: morphological structure of the tumor (<italic>p </italic>= 0.73), radiation therapy of the primary tumor (<italic>p </italic>= 0.38), chemotherapy (<italic>p </italic>= 0.46).</p><p><bold>Conclusion. </bold>Analysis of clinical and pathomorphological factors allowed to identify an unfavorable prognosis group in patients with penile cancer for a personalized approach to improve survival rates.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель</bold><bold> </bold><bold>исследования</bold><bold> </bold>– оценить влияние факторов прогноза на показатели выживаемости больных раком полового члена (РПЧ) и выделить группы пациентов благоприятного и неблагоприятного прогноза.</p><p><bold>Материалы и методы. </bold>Проведен ретроспективный анализ данных 197 больных РПЧ, которым проводилось лечение на базе Московской городской онкологической больницы № 62 и Клинического онкологического диспансера (Омск) в период с 1997 по 2023 г.</p><p><bold>Результаты. </bold>Статистически значимыми факторами прогноза, влияющими на показатели выживаемости пациентов с РПЧ, при однофакторном анализе (<italic>log-rank</italic>-тест, <italic>р </italic>&lt;0,05) и многофакторном регрессионном анализе Кокса являются клиническая стадия (I–IV), стадия Т (Т1–Т3), край резекции (R0–R1), категория N (N0–N3), лимфоваскулярная инвазия, экстранодальное распространение метастаза в паховых лимфатических узлах, некроз первичной опухоли, поражение подвздошных лимфатических узлов. Факторами без значимого влияния на выживаемость являются морфологическая структура опухоли (<italic>р </italic>= 0,73), проведение лучевой терапии на первичную опухоль (<italic>р </italic>= 0,38), проведение химиотерапии (<italic>р </italic>= 0,46).</p><p><bold>Заключение.</bold><bold> </bold>Анализ клинико-патоморфологических факторов позволил выделить группу неблагоприятного прогноза у пациентов с РПЧ для персонализированного подхода в целях повышения показателей выживаемости.</p></trans-abstract><kwd-group xml:lang="en"><kwd>penile cancer</kwd><kwd>survival rate</kwd><kwd>mean life expectancy</kwd><kwd>risk factor</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак полового члена</kwd><kwd>выживаемость</kwd><kwd>средняя продолжительность жизни</kwd><kwd>фактор риска</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Clinical guidelines. Penile cancer, 2020-2021-2022 (31.01.2023). Approved by the Ministry of Health of Russia. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Клинические рекомендации. Рак полового члена, 2020-2021-2022 (31.01.2023). Утверждены Минздравом РФ.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Malignant tumors in Russia in 2021 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Volkova M.I. Penile cancer. Zlokachestvennye opukholi = Malignant Tumors 2015;4(special issue 2):91–4. (In Russ.). DOI: 10.18027/2224-5057-2015-4s2-91-94.</mixed-citation><mixed-citation xml:lang="ru">Волкова М.И. Рак полового члена. Злокачественные опухоли 2015;4(спецвыпуск 2):91–4. DOI: 10.18027/2224-5057-2015-4s2-91-94</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Khalafyan E.A., Volkova M.I., Gurariy L.L. et al. Factors of prognosis in cancer of the penis. Onkourologiya = Cancer Urology 2005;1(3):55–60. (In Russ.). Available at: https://doi.org/10.17650/1726-9776-2005-1-3-55-60</mixed-citation><mixed-citation xml:lang="ru">Халафьян Э.А., Волкова М.И., Гурарий Л.Л. и др. Факторы прогноза при раке полового члена. Онкоурология 2005;1(3):55–60. Доступно по: https://doi.org/10.17650/1726-9776-2005-1-3-55-60</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Kuranov Yu.Yu., Sakalo V.S., Mrachkovsliy V.V. et al. Prognostic factors in patients with penile cancer and their role in choosing the treatment tactics. Onkologiya = Oncology 2010;12(1). (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Куранов Ю.Ю., Сакало В.С., Мрачковский В.В. и др. Факторы прогноза у больных раком полового члена и их значение при выборе тактики лечения. Онкология 2010;12(1).</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Li Z.S., Ornellas A.A., Schwentner C. et al. A modified clinicopathological tumor staging system for survival prediction of patients with penile cancer. Cancer Commun (Lond) 2018;38:68. DOI: 10.1186/s40880-018-0340-x</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Thomas W.F., Philippe E.S., Neeraj A. Penile Cancer, Version 1. 2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Li P., Song N., Yin C. et al. Glans-preserving surgery for superficial penile cancer. J Androl 2012;33(3). DOI: 10.2164/jandrol.111.013896</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>O’Kane H.F., Pahuja A., Ho K.J. et al. Outcome of glansectomy and skin grafting in the management of penile cancer. Adv Urol 2011:2011:240824. DOI: 10.1155/2011/240824</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Khurud P., Gupta A., Krishnatry R. et al. Optimizing target volume for adjuvant radiation therapy in penile cancer. Pract Radiat Oncol 2023;13(3):e270–7. DOI: 10.1016/j.prro.2022.11.001</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ravi P., Pagliaro L.C. Multimodal therapy in the management of advanced penile cancer. Urol Clin North Am 2016;43:469–79. DOI: 10.1016/j.ucl.2016.06.008</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Chahoud J., Kohli M., Spiess P.E. Management of advanced penile cancer. Mayo Clin Proc 2021;96:720–32. DOI: 10.1016/j.mayocp.2020.06.031</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Pecoraro A., Elst L., Roussel E. et al. Impact of the standardization of penile cancer care on the quality of care, outcomes, and academic-driven centralization in a single eUROGEN referral center. Eur Urol Focus 2023:S2405-4569(23)00175-X. DOI: 10.1016/j.euf.2023.07.003</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kamel M.H., Khalil M.I., Davis R. et al. Management of the clinically negative (cN0) groin penile cancer patient: a review. Urology 2019;131:5–13. DOI: 10.1016/j.urology.2019.05.005</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zhang W., Gao P., Gao J. et al. A clinical nomogram for predicting lymph node metastasis in penile cancer: a SEER-based study. Front Oncol 2021;11:640036. DOI: 10.3389/fonc.2021.640036</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ficarra V., Akduman B., Bouchot O. et al. Prognostic factors in penile cancer. Urology 2010;76(2):S66–73. DOI: 10.1016/j.urology.2010.04.008</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Hakenberg O.W., Dräger D.L., Erbersdobler A. et al. The Diagnosis and treatment of penile cancer. Dtsch Arztebl Int 2018;115(39):646–52. DOI: 10.3238/arztebl.2018.0646</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Li Z., Guo S.,Wu Z. Proposal for reclassification of N staging system in penile cancer patients, based on number of positive lymph nodes. Cancer Sci 2018;109(3):764–70. DOI: 10.1111/cas.13484</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zekan D.S., Dahman A., Hajiran A.J. et al. Prognostic predictors of lymph node metastasis in penile cancer: a systematic review. Int Braz J Urol 2021;47(5):943–56. DOI: 10.1590/S1677-5538.IBJU.2020.0959</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Pinkheaw N., Sathitruangsak C., Tanthanuch M., Bejrananda T. Real world data of recurrent and survival rates of penile cancer patients in Songklanagarind hospital: tumor stage as a predictor for disease-free survival. Int J Urol 2024;31(2):144–53. DOI: 10.1111/iju.15326</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Chipollini J., Pollock G., Hsu C.H. et al. National trends and survival outcomes of penile squamous cell carcinoma based on human papillomavirus status. Cancer Med 2021;10(21):7466–74. DOI: 10.1002/cam4.4258</mixed-citation></ref></ref-list></back></article>
